BeOne Medicines

BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide.

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of n

early 12,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-events/

06/17/2026

We asked our team, and Tim Howard, what One Save Changes Everything means to them.

The answers went beyond the game ⚽ – hope, resilience, purpose, and the determination to keep pushing forward.

As the world watches every save this summer, we’re inspired by that mindset in our work to help advance cancer care. Learn more: https://bit.ly/3PUMtg6

06/11/2026

This time of year, all eyes are on the saves. But the save is just part of the story – it's everything behind it that makes it count. When your opponent is as tough as cancer, making the save starts with preparation, focus and the right game plan. Learn more: https://bit.ly/3PUMtg6

06/03/2026

As the world gets ready for the big tournament next week, we were excited to showcase our initiative with former US Men’s National Team goalkeeper, Tim Howard, at .

Whether it’s on the field or in our shared purpose against cancer – we believe One Save Changes Everything.

left Chicago feeling proud of what we’ve accomplished and energized for what’s next. Together, we are how the world stops cancer.

Learn more at BeOneSave.com

Innovation in CLL care is moving quickly — but patient access hasn’t kept up.That’s why we are working with Charles Rive...
06/02/2026

Innovation in CLL care is moving quickly — but patient access hasn’t kept up.

That’s why we are working with Charles River Associates and key partners on a first-of-its-kind report, 𝙒𝙝𝙚𝙣 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙤𝙣 𝙊𝙪𝙩𝙥𝙖𝙘𝙚𝙨 𝘼𝙘𝙘𝙚𝙨𝙨: 𝘾𝙡𝙤𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙂𝙖𝙥 𝙞𝙣 𝘾𝙇𝙇 𝘾𝙖𝙧𝙚 — exploring the disconnect between progress in chronic lymphocytic leukemia (CLL) treatment and the barriers that still stand in the way of patients benefiting from that innovation.

This is the first in a series of report highlights examining key pressure points across the CLL care journey – from delays in biomarker testing to inconsistent guideline adherence and insurance-related access challenges – and the need for more coordinated, patient-centered solutions.

Patients should have the opportunity to receive the right treatment at the right time.

Explore the report overview here: https://beonemedicines.com/patients/our-commitment-to-patients/

Stay tuned for more insights!

06/02/2026

At , we're highlighting long-term data in CLL. 78-months of follow-up from a Phase 3 study provides important insight into the importance of durable outcomes. Hear from Amit Agarwal, M.D., Ph.D. on why these data matter just as much as initial response in CLL.

Learn more: https://beonemedicines.com/stories/asco-2026-translating-cancer-research/?utm_campaign=beone_01_pan_ub_corpaff_all_us_fy26_asco26&utm_medium=social&utm_source=facebook_0526-mult-prc-001&utm_content=all_learn-more&utm_term=term

BeOne was proud to serve as presenting sponsor of the International Waldenstrom's Macroglobulinemia Foundation U.S. Educ...
05/12/2026

BeOne was proud to serve as presenting sponsor of the International Waldenstrom's Macroglobulinemia Foundation U.S. Educational Forum – one of the largest U.S. gatherings dedicated to Waldenstrom Macroglobulinemia (WM).

At the opening session we presented, “Empowered by AI: Navigating Blood Cancer Care Through Technology,” exploring how real-world AI is reshaping blood cancer care. A clear theme emerged: trust. Building AI that is transparent, responsible, and grounded in high-quality data is essential to enabling confident, shared decision making between patients and clinicians.

At BeOne, we believe trust is what unlocks AI’s potential – expanding access to knowledge, supporting better conversations, and empowering patients to lead in their own care. Engaging directly with the WM community at this important forum reinforced why trust, patient-centric innovation, and shared decision making must remain at the heart of everything we do. Thank you to IWMF, the expert faculty, and the entire WM community for the meaningful conversations and continued collaboration.


Address

55 Cambridge Parkway, Suite 700W
Cambridge, MA
02142

Telephone

+18778285568

Website

,

Alerts

Be the first to know and let us send you an email when BeOne Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category